Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Emma Woodward

Manchester University NHS Foundation Trust

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Biostatistics

90%

Cell Biology

30%

Medical Science

80%

Cancer Biology

60%

Genomic

50%

Ovarian Cancer

40%

Genomic Instability

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30–39 over grade 3 aged 40–49 years?

Article Link

Year:

2024

Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene

Article Link

Year:

2024

ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dubé syndrome

Article Link

Year:

2024

Cascade screening in HBOC and Lynch syndrome

Article Link

Year:

2024

Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants

Article Link

Year:

2024

Germline testing ofBRCA1,BRCA2,PALB2andCHEK2c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing ofATM,RAD51CandRAD51Din over 400

Article Link

Year:

2024

Is reflex germline BRCA1/2 testing necessary in women diagnosed with non-mucinous high-grade epithelial ovarian cancer aged 80 years or older?

Article Link

Year:

2023

Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers

Article Link

Year:

2023

MSH2is the very young onset ovarian cancer predisposition gene, notBRCA1

Article Link

Year:

2023

TP53c.455C>T p.(Pro152Leu) pathogenic variant is a lower risk allele with attenuated risks of breast cancer and sarcoma

Article Link

Year:

2023

Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer

Article Link

Year:

2023

Hereditary renal cancer patient and public involvement group: a collaborative, consensus decision process to develop a communication tool for patient use

Article Link

Year:

2023

Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

Article Link

Year:

2023

Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer

Article Link

Year:

2022

Reclassification of clinically-detected sequence variants

Article Link

Year:

2022

30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes

Article Link

Year:

2022

Collaborators13

Elaine Harkness

The University of Manchester

UNITED KINGDOM

William Newman

The University of Manchester

UNITED KINGDOM

Anthony Howell

The University of Manchester

UNITED KINGDOM

Miranda Durkie

Deputy head of rare disease

UNITED KINGDOM

Richard Edmondson

The University of Manchester

UNITED KINGDOM

Emma Crosbie

The University of Manchester

UNITED KINGDOM

Robert Morgan

The University of Manchester

UNITED KINGDOM

EAMONN MAHER

Professor, Head of Department

University of Cambridge

UNITED KINGDOM

Miriam Smith

Senior Lecturer in Cancer Genomics

The University of Manchester

UNITED KINGDOM

Nicola Flaum

The University of Manchester

UNITED KINGDOM

Gareth Evans

The University of Manchester

UNITED KINGDOM

Gordon Jayson

The University of Manchester

UNITED KINGDOM

Jamie Ellingford

The University of Manchester

UNITED KINGDOM

How do I reach out?

Meet Kite AI